# Jonathan Talbot

> Jonathan Talbot is a British, Basel-based biotech executive, Mosanna Therapeutics co-founder and founding CEO, and current CEO of Melodia Therapeutics. His career combines a pharmacy doctorate, finance training, nearly a decade at Roche, and company building backed by more than $85 million in Mosanna financing. He won the 2026 Strüngmann Award and is a non-executive director of Heparin Therapeutics.

- **Role:** Chief Executive Officer at Melodia Therapeutics
- **Organizations:** Melodia Therapeutics, Mosanna Therapeutics, Roche, Heparin Therapeutics
- **Nationality:** British
- **Education:** PhD in Pharmacy, King’s College London, Master’s in Finance, ESCP Business School
- **Known for:** Led Mosanna through seed and Series A financings totaling more than $85 million, according to his current official biography., Winner of the 2026 Strüngmann Award, carrying a €100,000 prize., Selected for Venture Leaders Biotech 2023.

## Career timeline

- **2007** — Completed a PhD at King’s College London.
- **2007-2008** — Studied finance at ESCP; thesis compared valuation approaches for early-stage biotechnology.
- **Before 2022; exact dates unverified** — Spent nearly a decade at Roche, including Global Scientific Director and Pharma Partnering roles.
- **2022** — Co-founded Mosanna Therapeutics with Forty51 Ventures; publicly confirmed as CEO on July 13.
- **2023** — Mosanna completed its seed syndicate; Talbot joined Venture Leaders Biotech in Boston.
- **2025-06** — Mosanna announced an $80 million Series A and appointed David Weber as President and CEO.
- **2025-09** — Melodia Therapeutics announced Talbot as Chief Executive Officer on September 2.
- **2026-09** — Won the Strüngmann Award in Munich on September 15.

## Achievements

- Led Mosanna through seed and Series A financings totaling more than $85 million, according to his current official biography.
- Winner of the 2026 Strüngmann Award, carrying a €100,000 prize.
- Selected for Venture Leaders Biotech 2023.
- Non-executive director at Heparin Therapeutics.

## Latest updates

- **2026-09** — Won the 2026 Strüngmann Award on September 15 in Munich.
- **2026-02** — Melodia announced a U.S. patent grant supporting its lead program on February 25.
- **2025-09** — Melodia announced his CEO appointment on September 2.

## Links

- LinkedIn: https://www.linkedin.com/in/jonathan-talbot-33a96849/

---

Profile page: https://yespress.io/jonathan-talbot
Published by YesPress — https://yespress.io
Last updated: 2026-10-14